Clinical Trials | September 26, 2025
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
For people with relapsed or refractory diffuse large B-cell lymphoma
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Subscribe To Our Newsletter & Stay Updated
